- EpiFinder™ Platform generates quantitative data at
scale, with unprecedented speed and cost-efficiency
- EpiFinder Genome generates 192 genome-wide
profiles by simultaneously targeting up to 8 markers in up to 24
samples or independent replicates
SOLNA, Sweden, June 18,
2024 /PRNewswire/ -- Epigenica, a start-up bringing
the first multiplex, high-throughput tools to epigenomic research,
today unveiled its EpiFinder™ Platform with a patented
high-throughput, multiplexing, quantitative ChIP-seq (hmqChIP-seq)
technology and launched EpiFinder Genome for comprehensive
genome-wide profiling. EpiFinder Genome, the company's flagship
product and the first commercial kit of its kind, simultaneously
targets up to eight markers in up to 24 samples or independent
replicates, generating quantitative data for in-depth insights into
biomedical research, drug discovery and development, diagnostics,
and precision medicine.
"We are incredibly excited today to share with the global
scientific community our EpiFinder platform, a groundbreaking
technology for epigenomic research, and to commercially launch
EpiFinder Genome," said Epigenica CEO and co-founder Mohamad Takwa, PhD. "The development of these
technologies has been a true labor of love for our team and marks
an important milestone for Epigenica as we advance our mission to
bring unprecedented scale, speed, and affordability to the rapidly
growing field of epigenetics."
External factors, such as aging, the environment, and lifestyle,
can play an essential role in how genes function by making
long-lived chemical modifications, or epigenetic marks, to our DNA
or histone proteins that wrap the DNA. While epigenetics holds
great promise for basic science, drug discovery and development,
diagnostics, and precision medicine, current technologies have
shortcomings in speed and don't produce quantitative data at scale,
impeding innovation in the field.
Epigenica's EpiFinder combines simultaneous multiplexing and
high-throughput screening for the first time in one product,
enabling researchers to streamline large-scale experiments and
generate quantitative data at scale to advance discoveries. At its
core is the hmqChIP-seq technology and proprietary LACODE
(Ligation-sensitive Amplification with Coded Adaptor) adaptor
design and barcoding technology, which significantly improves DNA
barcoding.
"With the ability to generate quantitative data at scale,
faster, and more cost-efficiently than ever before, EpiFinder
overcomes critical barriers to epigenetics research, and we believe
it will usher in a new era in epigenomics and scientific
innovation," said Epigenica co-founder and Chief Scientific Officer
Simon Elsässer, Ph.D.
EpiFinder Genome is the first product in the EpiFinder family,
which will offer kits that scale from genome-wide detail with high
sequencing depth to global quantifications based on low-depth
sequencing. EpiFinder Genome generates 192 genome-wide profiles in
a fraction of the time it takes to perform 192 parallel ChIP-seq
experiments. It offers intrinsically quantitative comparisons
across as many as eight markers in up to 24 samples or independent
replicates. With superior barcoding capabilities, EpiFinder Genome
reduces background noise and offers greater specificity compared to
current state-of-the-art approaches. The kit also includes an
open-source, custom-designed pipeline analysis software for
analyzing the vast quantitative data generated from EpiFinder
Genome.
Other features and benefits include:
- High-quality data
- Easy to use pooled workflow (3-day, 14-hour hands-on)
- 1 M cells/sample requirement for profiling up to
8 hPTMs
- Validated with cells and tissue
- Validated with native and fixed starting material
- Consistent, reproducible, and easy-to-interpret results
"The EpiFinder Genome kit offers an excellent opportunity for
labs with limited previous experience in ChIP-seq or similar
methods to obtain high-quality ChIP-seq data – without significant
time investment," says beta tester Björn Reinius, Associate
Professor at the Karolinska Institute
with a research focus on X-chromosome inactivation. "With minimal
optimization, the well-described steps enable users to generate
quantitative ChIP-seq libraries and to perform preliminary data
analyses."
EpiFinder Genome is available now, and more information may be
found at www.epigenica.se.
About Epigenica
Epigenica is a life sciences technology company at the forefront
of innovations in epigenetic research. The company's EpiFinder
platform enables researchers to perform comprehensive epigenetic
studies at unprecedented speed, scalability, and
affordability. Epigenica is building a portfolio of products
based on the EpiFinder platform to offer comprehensive
high-throughput profiling at different depths of detail with an
array of possible starting materials. The platform is powered by
the company's patented and proprietary high-throughput, multiplex,
quantitative ChIP-seq technology (hmqChIP), the first commercial
kit of its kind. With the advantages of the EpiFinder platform,
Epigenica is helping researchers advance biomedical research, drug
discovery and development, precision medicine, diagnostics, and
therapeutics for aging and longevity.
Epigenica was founded in Stockholm,
Sweden, in 2020 and is venture-funded.
Contact
Corporate
Epigenica CEO Mohamad Takwa,
Ph.D.
mt@epigenica.se
For Media
Susan
Thomas
Endpoint
Communications
susan@endpointcommunications.net
(619) 540-9195
Logo -
https://mma.prnewswire.com/media/2441490/Epigenica_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/epigenica-unveils-breakthrough-epigenetics-platform-launches-first-commercial-chip-seq-kit-for-high-throughput-multiplex-genome-wide-profiling-302175374.html
SOURCE Epigenica AB